Dr. Alipanahi is a computational biologist and machine learning scientist with over a decade of industry experience. Prior to cofounding Exai and becoming its Chief Scientific Officer, Babak served in research positions at Google and 23andMe, and cofounded Deep Genomics. As a postdoctoral fellow at the University of Toronto, he won the universitys prestigious Invention of the Year award in 2016 for his research on using deep learning for modeling biological processes. Babak has a Ph.D. degree in computer science from the University of Waterloo in Canada, a masters degree in electrical engineering from the University of Tehran, and a bachelors degree in electrical engineering from Tehran Polytechnic in Iran.
Clinical Dx Showcase:
Exai Bio is a next-generation liquid biopsy company. The company's proprietary RNA and AI-based liquid biopsy platform delivers clinical insights into cancer biology.Its mission is to enable a world where cancer can be detected early, diagnosed accurately, and treated in a personalized way.
A novel oncRNA-based platform for liquid biopsy tests
OncRNAs enable a novel liquid biopsy strategy for early cancer detection and monitoring residual disease.
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative